Comparative effectiveness of subcutaneous sarilumab 200 mg biweekly, subcutaneous Tocilizumab 162 mg biweekly, and intravenous Tocilizumab 8 mg/kg every 4 weeks in patients with rheumatoid arthritis: a prospective cohort study
SAR-SC 200 mg biweekly initiation was associated with a statistically significantly greater decrease in disease activity than TCZ-SC 162 mg biweekly in IL-6Ri-naïve patients with RA. In contrast, no statistically significant differences were identified between TCZ-IV 8 mg/kg every 4 week and TCZ-SC 162 mg biweekly. However, the effect size of our findings should necessitate careful consideration of the cost difference between TCZ-SC 162 mg biweekly including its biosimilars and SAR-SC 200 mg biweekly.
Authors
- Chisato Ashida (ORCID: https://orcid.org/0000-0003-3137-0138)
- Sho Sendo (ORCID: https://orcid.org/0000-0002-7193-341X)
- Kosuke Ebina (ORCID: https://orcid.org/0000-0002-2426-1024)
- Yumiko Wada
- Motomu Hashimoto (ORCID: https://orcid.org/0000-0002-9241-060X)
- Kosaku Murakami (ORCID: https://orcid.org/0000-0001-5981-4648)
- Hidehiko Makino
- Yuji Nozaki (ORCID: https://orcid.org/0000-0003-2810-1519)
- Koichi Murata (ORCID: https://orcid.org/0000-0002-7896-3937)
- Takayuki Fujii (ORCID: https://orcid.org/0000-0002-5580-6912)
- Kenichiro Hata (ORCID: https://orcid.org/0000-0002-7809-7637)
- Akira Ōnishi (ORCID: https://orcid.org/0000-0002-3120-1273)
- Yonsu Son (ORCID: https://orcid.org/0000-0001-7244-7715)
- Wataru Yamamoto (ORCID: https://orcid.org/0000-0002-0810-4221)
- Shuichi Matsuda (ORCID: https://orcid.org/0000-0001-6796-6035)
- Ryu Watanabe (ORCID: https://orcid.org/0000-0002-1089-5296)
- H. Yamada (ORCID: https://orcid.org/0000-0002-8090-6755)
- Masao Tanaka
- Akio Morinobu (ORCID: https://orcid.org/0000-0002-4672-638X)
Institutions
- Kansai Medical University (JP)
- Kyoto University (JP)
- Kurashiki Central Hospital (JP)
- Kyoto University Hospital (JP)
- Osaka Metropolitan University (JP)
- Kobe University (JP)
- Osaka University of Pharmaceutical Sciences (JP)
- Kindai University (JP)
- The University of Osaka (JP)
Publication Details
- Journal
- Arthritis Research & Therapy
- Published
- 2025-03-07
- DOI
- https://doi.org/10.1186/s13075-025-03514-x
- Citations
- 5
- Primary Topic
- Rheumatoid Arthritis Research and Therapies
- Type
- article
- Field-Weighted Citation Impact
- 8.34
Funders
- Eli Lilly and Company
- Sanofi
- Eisai
- Chugai Pharmaceutical
- Eli Lilly Japan